Tennessee is currently home to 1907 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Tennessee -- Memphis, Memphis, Tennessee
Conditions: Colorectal Cancer
Register for Updates
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/07/2025
Locations: ClinSearch - Chattanooga - Shallowford Road- Site Number : 8400012, Chattanooga, Tennessee
Conditions: Coeliac Disease, Celiac Disease
Register for Updates
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Thompson Cancer Survival Ctr /ID# 242149, Knoxville, Tennessee
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852
Recruiting
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/07/2025
Locations: Baptist Memorial Healthcare, Memphis, Tennessee
Conditions: Metastatic Breast Cancer
Register for Updates
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
NCT06362265
Recruiting
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/07/2025
Locations: Lifedoc Research - Lenox Park Drive, Memphis, Tennessee
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Register for Updates
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
NCT06097832
Recruiting
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/07/2025
Locations: Baptist Memorial Hospital, Memphis, Tennessee
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair
NCT05929937
Recruiting
The investigators hypothesize that not prescribing opioids after uncomplicated, outpatient IHR will be non-inferior to prescribing opioids (5 tablets of Oxycodone, 5mg; or surgeon preference for intolerance) with respect to requests for opioid refills. Additionally, the investigators believe there will be no significant difference in postoperative readmission for pain quality of life at 30 days in either group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Tennessee Medical Center, Knoxville, Tennessee
Conditions: Postoperative Pain, Inguinal Hernia
Register for Updates
The Ailliance Post-Market Clinical Study
NCT05856370
Recruiting
The purpose of this clinical study is to collect performance and safety data for post-market Medtronic devices indicated for cranial and/or spinal indication(s). Subjects are enrolled and followed postoperatively to 24 months. The Ailliance clinical study is intended to collect data congruous with routine clinical care practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Tennessee Orthopaedic Alliance, Nashville, Tennessee
Conditions: Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
Register for Updates
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
NCT05845710
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
07/07/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Carotid Stenosis, Carotid Artery Diseases
Register for Updates
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622
Recruiting
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/07/2025
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Register for Updates
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904
Recruiting
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossove... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/07/2025
Locations: Baptist Cancer Center, Bartlett, Tennessee
Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma
Register for Updates